Omeros Corporation (OMER) - What Are Brokerages Thinking About This Stock?

Key Points

• Analysts hold a moderately bullish view of Omeros, with three buy ratings and two holds producing a “Moderate Buy” consensus. The average 12-month price target is $30.33, above the reported share price of $17.88.
• Omeros reported quarterly EPS of $0.02, beating the consensus estimate of a $0.27 loss, while revenue of $28.53 million exceeded the $12.69 million estimate. Analysts expect a full-year loss of approximately $0.37 per share.
• Insiders have been selling shares: company insiders sold 105,906 shares worth about $1.99 million over the past 90 days, while institutional investors and hedge funds own 48.79% of the stock.

Omeros Corporation (NASDAQ:OMER - Get Free Report) has been given an average rating of "Moderate Buy" by the five ratings firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $30.33.

A number of equities research analysts have recently commented on OMER shares. Wall Street Zen upgraded Omeros from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. HC Wainwright reissued a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Weiss Ratings upgraded Omeros from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $22.00 target price on shares of Omeros in a research report on Wednesday, October 14th. Finally, Zacks Research downgraded Omeros from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th.

Insider Buying and Selling

In other Omeros news, Director Arnold Hanish sold 10,000 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $18.95, for a total transaction of $189,500.00. Following the sale, the director owned 5,000 shares in the company, valued at approximately $94,750. The trade was a 66.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO David Borges sold 10,000 shares of the business's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the sale, the chief accounting officer owned 5,906 shares in the company, valued at approximately $111,918.70. The trade was a 62.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 105,906 shares of company stock worth $1,989,705. Company insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC raised its holdings in shares of Omeros by 75.3% during the third quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 758 shares during the period. GK Wealth Management LLC purchased a new stake in shares of Omeros in the 3rd quarter valued at approximately $65,000. Assetmark Inc. acquired a new position in Omeros in the 1st quarter worth approximately $38,000. International Assets Investment Management LLC boosted its stake in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 800 shares during the period. Finally, Leonteq Securities AG acquired a new position in Omeros in the 1st quarter worth approximately $106,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Trading Up 2.2%

NASDAQ:OMER opened at $17.88 on Thursday. Omeros has a twelve month low of $6.24 and a twelve month high of $21.24. The company has a 50-day moving average of $18.51 and a 200-day moving average of $13.41. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of 13.97 and a beta of 2.57.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. On average, research analysts forecast that Omeros will post -0.37 earnings per share for the current year.

About Omeros

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.